HARP harpoontx.com: Enterprise Value to EBITDA Ratio

Graphic logo of Harpoon Therapeutics, Inc. (HARP)

Harpoon Therapeutics (HARP) automates the creation of oncology drugs through AI and robotics while simultaneously minimizing the environmental footprint of its laboratories. The current EV/EBITDA multiple of the business on GURU.Markets reflects the valuation trend, where the figure serves as the target level. Integration into a major pharmaceutical holding has provided the company with powerful resources for antibody development, eliminating the risks of price wars.

Harpoon Tx - HARP Total Company Value to Operating Income Before Depreciation Ratio (period 07/04/2022 - 11/12/2026)

Summary analytical data breakdowns for harpoontx.com (HARP)

- stock price and consensus target price:
Stock Quotes Harpoon Tx|HARP - Average Forecast Price
- company stock capitalization data:
Market Valuation Harpoon Therapeutics Corp|HARP - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Harpoon Therapeutics|HARP - Book Valuation of Business|Market Value to Book Value Ratio harpoontx.com|HARP - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Harpoon Therapeutics|HARP - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Harpoon Therapeutics, Inc.|HARP - Company Aggregate Debts|Debt to Book Capitalization Ratio Harpoon Therapeutics Corp|HARP - Company Long-Term Indebtedness|Company Short-Term Debt Harpoon Therapeutics|Quick Liquidity Indicator harpoontx.com
- financial results and valuation multiples details:
HARP - Annual Net Income|Future Profit Harpoon Therapeutics|HARP - Market Price to Net Income Ratio|Forward P/E Multiple Harpoon Therapeutics|HARP - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Harpoon Therapeutics Corp|HARP - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Harpoon Therapeutics|HARP - Earnings per share for the trailing year|Quarterly EPS earnings growth harpoontx.com|HARP - Earnings growth in current year|Net earnings per share growth forecast for next year Harpoon Therapeutics
Fundamental company analysis:HARP (Harpoon Tx)
Original product of Harpoon Therapeutics Inc

For Harpoon Therapeutics (HARP), which integrates bioplatforms into a global buyer's structure, assessing business value relative to operational cash flow is critical. This metric compares the total enterprise value (EV) with earnings before interest, taxes, depreciation, and amortization, eliminating the impact of debt load and accounting policies. By analyzing changes in the EV/EBITDA multiple, an investor determines the degree of asset overheating during the consolidation of R&D capacities.

Competitor analysis for Harpoon Therapeutics

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA iobiotech.com (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio IMMX|EV/EBITDA Multiple ALXO (ALX Oncology)|Business Value to Operating Income Before Depreciation CUE|PDS Biotechnology Corp - EV/EBITDA Multiple|Company Value to EBITDA Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Liminatus - Business Value to Operating Income Before Depreciation|LVTX (LAVA Therapeutics NV) - EV/EBITDA Multiple|EV/EBITDA Multiple nextcure.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Leap Therapeutics, Inc. (LPTX)|INTS: Company Value to Operating Income Before Depreciation Ratio|Sensei Biotherapeutics, Inc. - Enterprise Value to EBITDA Ratio|Theriva Corp (TOVX) - Company Value to EBITDA|Gritstone Bio - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation KA (kinetabio.com)|NEXI: EV/EBITDA Multiple|Turnstone Biologics Corp. (TSBX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vaccinex, Inc